NasdaqCM - Nasdaq Real Time Price USD

Citius Oncology, Inc. (CTOR)

0.5900 +0.0360 (+6.50%)

As of 9:31:27 AM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

PR Newswire 6d ago

CTOR
+6.50%
CTXR
Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

InvestorsHub 2mo ago

CTOR
+6.50%
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

PR Newswire 2mo ago

CTOR
+6.50%
CTXR
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

PR Newswire 2mo ago

CTOR
+6.50%
CTXR
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

PR Newswire 3mo ago

CTOR
+6.50%
CTXR
$Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies$

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

PR Newswire 4mo ago

CTOR
+6.50%
CTXR
Citius raises $36.5m for Lymphir commercialisation

Pharmaceutical Technology 5mo ago

CTOR
+6.50%
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

PR Newswire 5mo ago

CTOR
+6.50%
Citius Oncology Ships First International Order of LYMPHIR™ to Europe

PR Newswire 6mo ago

CTOR
+6.50%
CTXR
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

PR Newswire 6mo ago

CTOR
+6.50%
CTXR
Citius Oncology and Uniphar sign European distribution deal for Lymphir

Pharmaceutical Technology 8mo ago

CTOR
+6.50%
CTXR
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

PR Newswire 8mo ago

CTOR
+6.50%
CTXR

Performance Overview

Return	CTOR	S&P 500 (^GSPC)
YTD	-44.60%	+10.73%
1-Year	-67.98%	+11.11%
3-Year	-94.92%	+81.91%

U.S. markets close in 6h 19m

Citius Oncology, Inc. (CTOR)

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Citius raises $36.5m for Lymphir commercialisation

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Citius Oncology Ships First International Order of LYMPHIR™ to Europe

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

Citius Oncology and Uniphar sign European distribution deal for Lymphir

Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar